AbbVie has launched Boey in Europe, a botulinum toxin formulation engineered for faster onset compared to Botox. The product represents a differentiated entry point in a market where onset speed—traditionally 3–7 days for standard toxins—has become a competitive lever, particularly among practitioners seeking to reduce patient wait time and improve treatment satisfaction.